A Theranostic And Precision Medicine Approach For Female Specific Cancers

A Theranostic and Precision Medicine Approach for Female-Specific Cancers provides information regarding ongoing research and clinical data surrounding female specific cancers (breast, cervical, ovarian and endometrial cancers). The book encompasses detailed descriptions about diagnostics and therapeutic options for easy understanding, focusing on the subject matter with a broader range of treatment options. In addition, it explores new theranostics, i.e., diagnostic, therapeutic and precision medicine strategies currently being developed for FSCs. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of biomedical field who need to understand the most recent and promising approaches to manage FSCs. Explores new diagnostic biomarkers surrounding the early detection and prognosis of FSCs Examines new genetic and molecularly targeted approaches for the treatment of these aggressive diseases Discusses new theranostic approaches that combine diagnosis and treatment through the use of nanotechnology in FSCs Addresses how these various advances can be integrated into a precision and personalized medicine approach that can eventually enhance patient care

Design of Nanostructures for Theranostics Applications focuses on the theranostics applications of nanostructures. In particular, multifunctional nanoparticles for diagnostics and treatment of different diseases, including those relating to the blood-brain barrier, are discussed in detail. Chapters explore different type of nanostructures, covering design, fabrication, functionalization and optimization, helping readers obtain the desired properties. Written by a diverse range of international academics, this book is a valuable reference resource for those working in both nanoscience and the pharmaceutical industry. Explores how the design of a range of nanomaterials make them effective theranostic agents, including multifunctional core-shell nanostructures, mesoporous silica nanoparticles, and quantum dots Shows how nanomaterials are used effectively for a range of diseases, including breast cancer, prostate cancer and neurological disorders Assesses the pros and cons of using different nanomaterials for different types of treatment

Multifunctional Theranostic Nanomedicines in Cancer focuses on new trends, applications, and the significance of novel multifunctional nanotheranostics in cancer imaging for diagnosis and treatment. Cancer nanotechnology offers new opportunities for cancer diagnosis and treatment. Multifunctional nanoparticles harboring various functions—including targeting, imaging, and therapy—have been intensively studied with the goal of overcoming the limitations of conventional cancer diagnosis and therapy. Thus theranostic nanomedicines have emerged in recent years to provide an efficient and safer alternative in cancer management. This book covers polymer-based therapies, lipid-based therapies, inorganic particle-based therapies, photo-related therapies, radiotherapies, chemotherapies, and surgeries. Multifunctional Theranostic Nanomedicines in Cancer offers an indispensable guide for researchers in academia, industry, and clinical settings; it is also ideal for postgraduate students; and formulation scientists working on cancer. Provides a comprehensive resource of recent scientific progress and novel applications of theranostic nanomedicines Discusses treatment options from a pharmaceutical sciences perspective Includes translational science and targeted CNS cancer treatment

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies. This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting. Provides detailed information on traditional and novel diagnostic tools for hepatocellular carcinoma Discusses promising targeted therapies, both available and in development, explaining the best option to use for specific cases Brings recent findings in immunotherapies, immune checkpoint inhibitors and nanotechnology-based therapeutic approaches for treatment of HCC

Nanocarriers for the Delivery of Combination Drugs focuses on the role of nanocarriers in the delivery of combination drugs for the management and treatment of various diseases. Nanocarriers belonging to the category of polymeric nanoparticles, dendrimers, lipidic nanocarriers (like nanoemulsions), liposomes, solid lipid nanoparticles, nanostructured lipid carriers are now being used in the drug delivery of combination drugs. This book helps readers assimilate all the information available surrounding the application of various nanocarrier technologies for the delivery of combination drugs of synthetic and natural origin, including small and large molecules. This is an important reference source for pharmaceutical scientists and biomaterials scientists who are looking to gain an increased understanding on how nanotechnology is improving the efficiency of combination drug delivery. Outlines how nanocarriers are used to enhance combination drug delivery systems Assesses the major challenges of delivering combination drugs successfully, and explains how nanocarriers can help meet these challenges Explores the characteristics of a variety of nanocarrier material types

Targeted Cancer Imaging: Design and Synthesis of Nanoplatforms based on Tumour Biology reviews and categorizes imaging and targeting approaches according to cancer type, highlighting new and safe approaches that involve membrane-coated nanoparticles, tumor cell-derived extracellular vesicles, circulating tumor cells, cell-free DNAs, and cancer stem cells, all with the goal of pointing the way to developing precise targeting and multifunctional nanotechnology-based imaging probes in the future. This book is highly multidisciplinary, bridging the knowledge gap between tumor biology, nanotechnology, and diagnostic imaging, and thus making it suitable for researchers ranging from oncology to bioengineering. Although considerable efforts have been conducted to diagnose, improve and treat cancer in the past few decades, existing therapeutic options are insufficient, as mortality and morbidity rates remain high. One of the best hopes for substantial improvement lies in early detection. Recent advances in nanotechnology are expected to increase our current understanding of tumor biology, allowing nanomaterials to be used for targeting and imaging both in vitro and in vivo experimental models. Gives understanding of cancer biology that is appropriate for students and researchers in engineering and nanotechnology Demonstrates cancer targeting strategies of multifunctional nanotechnology-based imaging probes Shows how to design, synthesize and apply cancer imaging nanostructures

In the new edition of this very successful book, European and North American experts present the state of the art in diagnostic and therapeutic radionuclide procedures. The aim is to examine established and emerging clinical applications in detail, rather than to consider everything included in the comprehensive texts already available within the field. This “practical” approach ensures that the book will be a valuable guide for nuclear medicine physicians, technologists, students, and interested clinicians alike. This edition of Clinical Nuclear Medicine has been extensively revised to take account of recent developments. The roles of SPECT/CT, PET/CT, and PET/MRI are clearly explained and illustrated, and the coverage extended to encompass, for example, novel PET tracers and therapeutic radionuclides, advanced techniques of brain imaging, and the development of theranostics. Readers will be fully persuaded of the ever-increasing value of nuclear medicine techniques in depicting physiology and function and complementing anatomic modalities such as CT, MRI, and ultrasound.

Aiding researchers seeking to eliminate multi-step procedures, reduce delays in treatment and ease patient care, Cancer Theranostics reviews, assesses, and makes pertinent clinical recommendations on the integration of comprehensive in vitro diagnostics, in vivo molecular imaging, and individualized treatments towards the personalization of cancer treatment. Cancer Theranostics describes the identification of novel biomarkers to advance molecular diagnostics of cancer. The book encompasses new molecular imaging probes and techniques for early detection of cancer, and describes molecular imaging-guided cancer therapy. Discussion also includes nanoplatforms incorporating both cancer imaging and therapeutic components, as well as clinical translation and future perspectives. Supports elimination of multi-step approaches and reduces delays in treatments through combinatorial diagnosis and therapy Fully assesses cancer theranostics across the emergent field, with discussion of biomarkers, molecular imaging, imaging guided therapy, nanotechnology, and personalized medicine Content bridges laboratory, clinic, and biotechnology industries to advance biomedical science and improve patient management

Gastric cancer is one of the most common and potentially lethal gastrointestinal malignancy, but it is now at the forefront of modern oncology due to new discoveries. In recent years, the field of gastric cancer has been transformed by many notable developments in both the diagnostic area and the therapeutic strategies. The main aim of the text is to propose a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for oncologists, pathologists, surgeons and researchers with an interest in gastric cancer. The first chapters will review the interplay between pathogens and especially H. pylori, inflammation, genomic instability, and tumorigenesis. Secondly, an exhaustive overview of the diagnosis of gastric cancer from a clinical/endoscopic and pathologic perspectives will be illustrated. Two specific chapters will deal with tissue and serum biomarkers with an important role in diagnosis as well as prognostic and predictive markers of response to specific therapy. A central section of the book will focus on treatment options available today for patients. Surgery is the cornerstone of treatment for gastric cancer; however, the prognosis of patients with locally advanced disease is still poor even after curative resection. Therefore, in order to improve the prognosis of patients, especially with advanced stage, a multimodal strategy is advisable and is thoroughly addressed in the appropriate section. With the advent of next-generation sequencing and new preclinical model technologies, the genomic landscape of gastric cancer has been delineated and molecular characterizations finalized to novel therapeutic targets of each molecular subtype have been identified. These advances are making it feasible to integrate clinical and phenotype-based diagnostic and therapeutic methods and are described in a dedicated section. The text will conclude with chapters focusing on the future direction of gastric cancer research in the precision medicine era: an in-depth analysis of non-coding RNAs and their role in gastric cancer, the impact of immunomodulation/immunotherapy and the perspectives of nano-medicine will be finally proposed to the audience. A brief review of the existing literature addressing the above mentioned topics will be present in each chapter. This text will serve as a useful resource for physicians and researchers dealing with, and interested in, this challenging malignancy. It will provide a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters will be written by experts in their fields and will include the most up to date scientific and clinical information.

Nanomedicines for Breast Cancer Theranostics addresses the translational aspects and clinical perspectives of breast cancer nanomedicine from a multidisciplinary perspective. The book summarizes research efforts at the preclinical and clinical stage of nanostructures and nanomedicine for dealing with the important challenge of nanomedicine translation in breast cancer theranostics. This book is an important resource for those working in both academia and industry, focusing on hot topics in biomaterials, biomedical engineering, drug delivery and oncology. Shows how the discovery of new nanomedicines is leading directly to an increase in the early-stage diagnosis of breast cancer Includes coverage of breast cancer nanomedicine standardization and characterization, highlighting newly developed treatments, diagnostics and treatment monitoring tools Explains why the design of nanobiomaterials make them effective drug carriers when treating breast cancer

The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. This Research Topic on Drug-Diagnostic Co-Development in Oncology aims to provide you with an insight into some of the diverse activities that constitute this new research area.

Advances in Cancer Research, Volume 139, provides invaluable information on the exciting and fast-moving field of cancer research. Original reviews are presented on a variety of topics relating to the rapidly developing intersection between nanotechnology and cancer research, with unique sections in the new release focusing on Exosomes as a theranostic for lung cancer, Nanotechnology and cancer immunotherapy, Ultrasound imaging agents and delivery systems, Dendronized systems for the delivery of chemotherapeutics, Thermosensitive liposomes for image-guided drug delivery, Supramolecular Chemistry in Tumor Analysis and Drug Delivery, Gold nanoparticles for delivery of cancer therapeutics, and Single cell barcode microchip for cancer research and therapy. Provides the latest information on cancer research Offers outstanding and original reviews on a range of cancer research topics Serves as an indispensable reference for researchers and students alike

Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy edited by Dr. Nagaraju, PhD., DSc. focuses on overriding the resistance from chemotherapeutic drugs with a broader range of treatment options. It particularly focuses on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways. This volume discusses topics such as pancreatic cancer biology, current therapeutic options, EMT, chemotherapy resistance mechanisms, and genetic manipulations and natural products to enhance the sensitivity of pancreatic cancer to chemotherapy. Additionally, it discusses small targeted molecules and pancreatic cancer trials, and nanotechnology-based drug delivery. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy is a valuable source for researchers and advanced students in cancer and oncology as well as clinicians and medical students who are interested in learning more about ways to break pancreatic cancer resistance to chemotherapy. Modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property by introducing new strategies and drugs Provides information about on-going research as well as clinical data on pancreatic cancer and detailed descriptions about therapeutic options for easy understanding Utilizes full color figures to help the understanding of the content and tables for easy comparison of information as well as quick access to it

This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.

This book illustrates the importance of transcription factors in gastrointestinal cancer progression and metastasis with regard to understanding the mechanism and target definition in drug discovery. Further, it describes the complex issues associated with cancer cell growth and metastasis. The respective chapters provide detailed information on the various types of transcription factors (NF-kB, HIF-1, STAT-3, E2F1, and Sp1) and gastric-associated cancers (esophagus, stomach, colorectal, liver and pancreatic cancers) in connection with specific functional studies like cell cycle, angiogenesis, migration, invasion and apoptosis. These transcription factors control the expression of several signaling pathways involved in tumor growth, making them ideal targets for gastrointestinal cancer therapy. In closing, the book provides comprehensive descriptions of the major challenges associated with gastrointestinal cancer therapy.

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.

Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.

This pocket book explains the significant and well-documented impact that PET/CT can have on the management of prostate cancer through the provision of high-quality evidence regarding function and structure. Up-to-date information is supplied on the relevance of PET/CT to diagnosis, treatment planning, and therapy, including the emerging role of PET/CT with PSMA. Readers will also find clear explanation of the relation of the clinical and pathological background to imaging and the value of PET/CT compared with conventional radiological imaging. The book will be an excellent asset for referring clinicians, nuclear medicine/radiology physicians, radiographers/technologists, and nurses who routinely work in nuclear medicine and participate in multidisciplinary meetings. It is published within the Springer series Clinicians’ Guides to Radionuclide Hybrid Imaging, which presents contributions from professionals worldwide who share a common purpose in promoting nuclear medicine as an important imaging specialty for the diagnosis and management of oncological and non-oncological conditions.

This book covers the most recent advances in using nanoparticles for biomedical imaging, including magnetic resonance imaging (MRI), magnetic particle imaging (MPI), nuclear medicine, ultrasound (US) imaging, computed tomography (CT), and optical imaging. Topics include nanoparticles for MRI and MPI, siRNA delivery, theranostic nanoparticles for PET imaging of drug delivery, US nanoparticles for imaging drug delivery, inorganic nanoparticles for targeted CT imaging, and quantum dots for optical imaging. This book serves as a valuable resource for the fundamental science of diagnostic nanoparticles and their interactions with biological targets, providing a practical handbook for improved detection of disease and its clinical implementation.